BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
IDF drops over 80 explosives on Tehran weapon production sites in latest strike - 2Islamic State group militants claim capture and execution of a Nigerian brigadier general
- 3Violence 'never part' of break-in plan, court told
- 4Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there
- 521 Things You Ought to Never Tell Your Childless Companion
- Posts falsely claim Malaysian minister to relocate public hospital for temple
- 7 Countries Where Newcomers Feel Most Welcome, and 3 Where They Often Don’t
- Discovery off Israel’s coast reveals earliest known 2,600-year-old shipment of raw iron
- Vote in favor of your #1 Sort of Convenience for a Family
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals
- L.A.'s most famous midcentury home, the Stahl House, is on the market for the 1st time, at $11K per square foot: See inside
- Child influencers helped power a booming industry. It's time for a reckoning.
- Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
